

# Andrew H Evans

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/248637/publications.pdf>

Version: 2024-02-01

89  
papers

4,765  
citations

136950

32  
h-index

98798

67  
g-index

90  
all docs

90  
docs citations

90  
times ranked

4153  
citing authors

#	ARTICLE	IF	CITATIONS
1	Time to diagnosis in younger-onset dementia and the impact of a specialist diagnostic service. <i>International Psychogeriatrics</i> , 2022, 34, 367-375.	1.0	38
2	Directional Deep Brain Stimulation for Parkinson's Disease: Results of an International Crossover Study With Randomized, Double-Blind Primary Endpoint. <i>Neuromodulation</i> , 2022, 25, 817-828.	0.8	34
3	The Diagnostic Challenge of Young-Onset Dementia Syndromes and Primary Psychiatric Diseases: Results From a Retrospective 20-Year Cross-Sectional Study. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2022, 34, 44-52.	1.8	13
4	Cerebrospinal fluid Alzheimer disease biomarkers for assessing cognitive and neuropsychiatric symptoms: Expanding the "toolkit" in the psychiatrist's diagnostic armamentarium. <i>Australian and New Zealand Journal of Psychiatry</i> , 2022, 56, 865-866.	2.3	1
5	Type 1 cryoglobulinemic neuropathy associated with lymphoplasmacytic lymphoma. <i>Acta Neurologica Belgica</i> , 2021, 121, 1887-1890.	1.1	0
6	A 10 year retrospective cohort study of inpatients with younger-onset dementia. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 294-301.	2.7	15
7	Characteristics of advanced Parkinson's disease patients seen in movement disorder clinics - Australian results from the cross-sectional OBSERVE study. <i>Clinical Parkinsonism &amp; Related Disorders</i> , 2021, 4, 100075.	0.9	4
8	Mortality in dementia is predicted by older age of onset and cognitive presentation. <i>Australian and New Zealand Journal of Psychiatry</i> , 2021, , 000486742110410.	2.3	9
9	A retrospective review of MRI features associated with metastasis-free survival in women with breast cancer: focusing on skin thickening and skin enhancement. <i>British Journal of Radiology</i> , 2021, 94, 20210472.	2.2	2
10	Oromandibular parafunction in chronic graft-versus-host disease: novel association and treatment approach. <i>Internal Medicine Journal</i> , 2021, 51, 1950-1953.	0.8	3
11	Autoimmune Encephalitis in Long-Standing Schizophrenia: A Case Report. <i>Frontiers in Neurology</i> , 2021, 12, 810926.	2.4	2
12	Sodium selenate as a disease-modifying treatment for progressive supranuclear palsy: protocol for a phase 2, randomised, double-blind, placebo-controlled trial. <i>BMJ Open</i> , 2021, 11, e055019.	1.9	4
13	Mortality in FTD: An Australian perspective. <i>Alzheimer's and Dementia</i> , 2021, 17, e058561.	0.8	0
14	The diagnostic challenge among young onset dementia syndromes and primary psychiatric diseases: Results of a retrospective, 20-year cross-sectional study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
15	Tractography-Guided Deep Brain Stimulation of the Anteromedial Globus Pallidus Internus for Refractory Obsessive-Compulsive Disorder: Case Report. <i>Neurosurgery</i> , 2020, 86, E558-E563.	1.1	7
16	A pilot study of the utility of cerebrospinal fluid neurofilament light chain in differentiating neurodegenerative from psychiatric disorders: A C-reactive protein™ for psychiatrists and neurologists?. <i>Australian and New Zealand Journal of Psychiatry</i> , 2020, 54, 57-67.	2.3	40
17	Functional neuroplasticity in response to cerebello-thalamic injury underpins the clinical presentation of tremor in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020, 26, 696-705.	3.0	10
18	OCD symptoms in succinic semialdehyde dehydrogenase (SSADH) deficiency: a case report. <i>BMC Psychiatry</i> , 2020, 20, 395.	2.6	4

#	ARTICLE	IF	CITATIONS
19	Parkinsonism as a Third Wave of the COVID-19 Pandemic?. Journal of Parkinson's Disease, 2020, 10, 1343-1353.	2.8	50
20	BeYOND: Biomarkers in younger-onset neurocognitive disorders – The first 50 participants. Alzheimer's and Dementia, 2020, 16, e040714.	0.8	0
21	Neurofilament light chain in psychiatric and neurodegenerative disorders: A –reactive protein™ for the brain?. Alzheimer's and Dementia, 2020, 16, e041347.	0.8	1
22	Sniffin' Sticks Screening 12 Test can assist in the clinical distinction between psychiatric disorders and neurological/neurodegenerative disorders. Alzheimer's and Dementia, 2020, 16, e042482.	0.8	0
23	Acoustic Speech Analytics Are Predictive of Cerebellar Dysfunction in Multiple Sclerosis. Cerebellum, 2020, 19, 691-700.	2.5	22
24	Pain and dyskinesia in Parkinson's disease may share common pathophysiological mechanisms – An fMRI study. Journal of the Neurological Sciences, 2020, 416, 116905.	0.6	6
25	OnabotulinumtoxinA treatment for MS-tremor modifies fMRI tremor response in central sensory-motor integration areas. Multiple Sclerosis and Related Disorders, 2020, 40, 101984.	2.0	3
26	Establishing apomorphine treatment in Thailand: understanding the challenges and opportunities of Parkinson's disease management in developing countries. Expert Review of Neurotherapeutics, 2020, 20, 523-537.	2.8	7
27	Brief Psychiatric Screening Questionnaire in Parkinson's Disease. Parkinson's Disease, 2019, 2019, 1-5.	1.1	0
28	Anti-Ma2-associated paraneoplastic encephalitis eat, sleep and repeat. Internal Medicine Journal, 2019, 49, 931-932.	0.8	5
29	Scales to assess impulsive and compulsive behaviors in Parkinson's disease: Critique and recommendations. Movement Disorders, 2019, 34, 791-798.	3.9	49
30	Parkinson's disease in the Western Pacific Region. Lancet Neurology, The, 2019, 18, 865-879.	10.2	116
31	Cerebrospinal fluid cannot be used to distinguish inflammatory myelitis from congestive myelopathy due to spinal dural arteriovenous fistula: case series. BMJ Neurology Open, 2019, 1, e000019.	1.6	3
32	Validation of a precision tremor measurement system for multiple sclerosis. Journal of Neuroscience Methods, 2019, 311, 377-384.	2.5	8
33	Objective measurement in routine care of people with Parkinson's disease improves outcomes. Npj Parkinson's Disease, 2018, 4, 10.	5.3	45
34	Neurocognitive correlates of medication-induced addictive behaviours in Parkinson's disease: A systematic review. European Neuropsychopharmacology, 2018, 28, 561-578.	0.7	10
35	Pain sensitivity in Parkinson's disease: Systematic review and meta-analysis. Parkinsonism and Related Disorders, 2018, 48, 17-27.	2.2	30
36	Treatment advances in Parkinson disease: Same script different cast?. Journal of Clinical Neuroscience, 2018, 47, 354-355.	1.5	2

#	ARTICLE	IF	CITATIONS
37	Deep brain stimulation for severe treatment-resistant obsessive-compulsive disorder: An open-label case series. Australian and New Zealand Journal of Psychiatry, 2018, 52, 699-708.	2.3	25
38	Parkinson disease: A systemic review of pain sensitivities and its association with clinical pain and response to dopaminergic stimulation. Journal of the Neurological Sciences, 2018, 395, 172-206.	0.6	20
39	What speech can tell us: A systematic review of dysarthria characteristics in Multiple Sclerosis. Autoimmunity Reviews, 2018, 17, 1202-1209.	5.8	79
40	Novel Functional MRI Task for Studying the Neural Correlates of Upper Limb Tremor. Frontiers in Neurology, 2018, 9, 513.	2.4	7
41	026â€¦Characteristics of advanced parkinsonâ€™s disease patients seen in movement disorder clinics â€œ“ australain results from the cross-sectional observe study. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, A11.1-A11.	1.9	0
42	Feasibility of Smartphone-Based Testing of Interference in Parkinsonâ€™s Disease. Neurodegenerative Diseases, 2018, 18, 133-142.	1.4	5
43	Novel Approach to Stem Cell Therapy in Parkinson's Disease. Stem Cells and Development, 2018, 27, 951-957.	2.1	39
44	Integrating Patient Concerns into Parkinsonâ€™s Disease Management. Current Neurology and Neuroscience Reports, 2017, 17, 3.	4.2	44
45	Practical approaches to commencing deviceâ€¢assisted therapies for Parkinson disease in Australia. Internal Medicine Journal, 2017, 47, 1107-1113.	0.8	14
46	Objective Measurement and Characterization of Sleep Benefit in Parkinson's Disease. Movement Disorders Clinical Practice, 2017, 4, 590-596.	1.5	9
47	Tremor in multiple sclerosis is associated with cerebello-thalamic pathology. Journal of Neural Transmission, 2017, 124, 1509-1514.	2.8	24
48	Subjective perception of sleep benefit in Parkinson's disease: Valid or irrelevant?. Parkinsonism and Related Disorders, 2017, 42, 90-94.	2.2	6
49	Evaluation of Nonmotor Symptoms in Diagnosis of Parkinsonism and Tremor. Parkinson's Disease, 2016, 2016, 1-6.	1.1	2
50	Validation of a Smartphone Application Measuring Motor Function in Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2016, 6, 371-382.	2.8	44
51	The efficacy of apomorphine â€œ“ A non-motor perspective. Parkinsonism and Related Disorders, 2016, 33, S28-S35.	2.2	30
52	Immortalized Parkinson's Disease lymphocytes have enhanced mitochondrial respiratory activity. DMM Disease Models and Mechanisms, 2016, 9, 1295-1305.	2.4	40
53	The relationship between specific cognitive defects and burden of care in Parkinson's disease. International Psychogeriatrics, 2016, 28, 275-281.	1.0	27
54	Neuropsychiatric manifestations of Parkinsonâ€™s disease. Australasian Psychiatry, 2016, 24, 529-533.	0.7	8

#	ARTICLE	IF	CITATIONS
55	Skin Picking Heraldng Parkinsonâ€™s Disease. Journal of Neuropsychiatry and Clinical Neurosciences, 2016, 28, e23-e24.	1.8	1
56	A guide to management of neuropsychiatric manifestations of Parkinsonâ€™s disease. Australasian Psychiatry, 2016, 24, 534-537.	0.7	4
57	Active surveillance for the management of localized prostate cancer: Guideline recommendations. Canadian Urological Association Journal, 2015, 9, 171.	0.6	184
58	Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease â€“ Clinical practice recommendations. Parkinsonism and Related Disorders, 2015, 21, 1023-1030.	2.2	126
59	Clinical spectrum of impulse control disorders in Parkinson's disease. Movement Disorders, 2015, 30, 121-127.	3.9	264
60	Canadian guidelines for the management of the small renal mass (SRM). Canadian Urological Association Journal, 2015, 9, 160.	0.6	45
61	Latent Autoimmune Diabetes in Stiff-Person Syndrome. Diabetes Care, 2014, 37, e214-e215.	8.6	7
62	Growth kinetics of small renal masses: A prospective analysis from the Renal Cell Carcinoma Consortium of Canada. Canadian Urological Association Journal, 2014, 8, 24.	0.6	44
63	Neuropsychiatric symptoms as the presenting feature of acquired hepatocerebral degeneration. Australian and New Zealand Journal of Psychiatry, 2014, 48, 959-960.	2.3	3
64	Regular Transition Zone Biopsy during Active Surveillance for Prostate Cancer May Improve Detection of Pathological Progression. Journal of Urology, 2014, 192, 1088-1093.	0.4	6
65	The anteromedial GPI as a new target for deep brain stimulation in obsessive compulsive disorder. Journal of Clinical Neuroscience, 2014, 21, 815-821.	1.5	52
66	A Conditioned Response as a Measure of Impulsive-Compulsive Behaviours in Parkinson's Disease. PLoS ONE, 2014, 9, e89319.	2.5	15
67	Topiramate for Abnormal Eating Behaviour in Frontotemporal Dementia. Behavioural Neurology, 2013, 27, 285-286.	2.1	21
68	Dyskinetic patients show rebound worsening of affect after an acute L-dopa challenge. Parkinsonism and Related Disorders, 2012, 18, 514-519.	2.2	14
69	Cue-induced striatal dopamine release in Parkinson's disease-associated impulsive-compulsive behaviours. Brain, 2011, 134, 969-978.	7.6	283
70	Dopamine agonist-induced substance addiction: The next piece of the puzzle. Journal of Clinical Neuroscience, 2011, 18, 191-192.	1.5	8
71	Progressive parkinsonism, oculomotor abnormalities and autonomic dysfunction: Clinicopathological case. Movement Disorders, 2011, 26, 424-429.	3.9	1
72	Compulsive use of dopaminergic drug therapy in Parkinson's disease: Reward and anti-reward. Movement Disorders, 2010, 25, 867-876.	3.9	48

#	ARTICLE	IF	CITATIONS
73	Impulsiveâ€compulsive spectrum behaviors in pathologically confirmed progressive supranuclear palsy. <i>Movement Disorders</i> , 2010, 25, 638-642.	3.9	33
74	Excessive hoarding in Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 1026-1033.	3.9	50
75	Punding in patients on dopamine agonists for restless leg syndrome. <i>Movement Disorders</i> , 2009, 24, 140-141.	3.9	24
76	Impulsive and compulsive behaviors in Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 1561-1570.	3.9	192
77	Do dyskinesia and pain share common pathophysiological mechanisms in Parkinson's disease?. <i>Movement Disorders</i> , 2008, 23, 1689-1695.	3.9	85
78	Impulse Control and Related Disorders in Parkinson's Disease. <i>Annals of the New York Academy of Sciences</i> , 2008, 1142, 85-107.	3.8	109
79	Dopamine agonist-induced pathological gambling in restless legs syndrome due to multiple sclerosis. <i>Movement Disorders</i> , 2007, 22, 590-591.	3.9	68
80	Pathological gambling in Parkinson's disease: Risk factors and differences from dopamine dysregulation. An analysis of published case series. <i>Movement Disorders</i> , 2007, 22, 1757-1763.	3.9	246
81	Punding and dyskinesias. <i>Movement Disorders</i> , 2006, 21, 2214-2217.	3.9	76
82	Compulsive drug use linked to sensitized ventral striatal dopamine transmission. <i>Annals of Neurology</i> , 2006, 59, 852-858.	5.3	435
83	Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: A prospective study using singleâ€dose challenges. <i>Movement Disorders</i> , 2005, 20, 151-157.	3.9	262
84	Punding in Parkinson's disease: Its relation to the dopamine dysregulation syndrome. <i>Movement Disorders</i> , 2004, 19, 397-405.	3.9	488
85	L-dopa-responsive Parkinson's syndrome in association with phenylketonuria: In vivo dopamine transporter and D2 receptor findings. <i>Movement Disorders</i> , 2004, 19, 1232-1236.	3.9	23
86	Recognition of a dopamine replacement therapy dependence syndrome in Parkinson's disease: a pilot studyâ†Supplementary. <i>Drug and Alcohol Dependence</i> , 2004, 76, 305-310.	3.2	58
87	Dopamine dysregulation syndrome in Parkinson's disease. <i>Current Opinion in Neurology</i> , 2004, 17, 393-398.	3.6	218
88	Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry?. <i>Lancet Neurology</i> , The, 2003, 2, 595-604.	10.2	278
89	The morbidity related to atrial fibrillation at a tertiary centre in one year: 9.0% of all strokes are potentially preventable. <i>Journal of Clinical Neuroscience</i> , 2002, 9, 268-272.	1.5	26